BioWednesday London 2 September 2015 Olswang, 90 High Holborn, London WC1V 6XX
Programme 14.00
Registration and networking
Session 1: Collaborative Opportunities with the Czech Republic 14.30 - Welcome 14.45 - Petr Müller, Regional Centre for Applied Molecular Oncology 15.00 - Vojtech Melenovský and Josef Kautzner, Institute for Clinical and Experimental Medicine 15.15 - Lukas Recek, MEDITOX s.r.o. 15.30 - Tea/Coffee Break 16.00 - Martin Vodák, SOTIO a.s. 16.15 - Martina Urbánková, AGEL Research a.s. 16.30 - Ondrej Sochor and Viola Galligioni, The International Clinical Research Center of St. Anne’s University Hospital in Brno 16.45 - Jirí Krechl, CzechInvest 17.00 - Closing remarks, tea and coffee
Session 2: What Constitutes Independence? 17.30 - Welcome from the host and chair Niall McAlister, Olswang 17.40 - Exploring Meritocracy in Grant Funding Davidson Ateh, BioMoti 18.00 - Accessing and Using Key Opinion Leaders - The Importance of Looking Outside your SAB Itziar Escudero, Insights in Life Sciences Ltd (ilS) 18.20 - Q&A with the speakers 18.50 - Introduction to Genesis 2015 Tony Jones, One Nucleus 19.05 - Networking over drinks and canapĂŠs 21.00
Event closes
Company Profiles Regional Centre for Applied Molecular Oncology RECAMO, translating the human cancer genome and proteome into treatment target identification, novel biomarkers for diagnosis and monitoring, and cancer drug response prediction. www.recamo.cz/en
Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec Research & development performed in BIOCEV is focused on the selected areas of biotechnologies and biomedicine. The scientific scope of BIOCEV has been divided into five research programmes, each of them dealing with a number of separate research projects. They are: Functional Genomics, Cellular Biology and Virology, Structural Biology and Protein Engineering, Biomaterials and Tissue Engineering, and Development of Diagnostic and Therapeutic Procedures. www.biocev.eu/en
Institute for Clinical and Experimental Medicine The largest Czech medical research and clinical hospital managed directly by the ministry of health which was established in 1971. For almost 40 years, the Institute for Clinical and Experimental Medicine has provided healthcare services at the highest level. The main objective of the institute is to continually improve healthcare for patients, to perfect medical procedures and apply the newest scientific findings in practice. Over its existence, IKEM has become one of the largest specialist clinical and scientific research workplaces in the Czech Republic, focusing on the treatment of cardiovascular diseases, organ transplants, diabetology and the treatment of metabolic diseases. www.ikem.cz/www/en
MediTox s.r.o MediTox s.r.o. is a GLP-certified Contract Research Organisation dedicated to pre-clinical research and development, having experience in a variety of compounds and therapeutic areas, with experts and associate teams able to conduct a number of experiments in full compliance to GLP standards and in compliance to other international guidelines (EMEA, ICH/VICH, OECD, US FDA, US EPA/OPPTS, ISO), closely connected with pharma and biomedical industries in the Czech Republic, EU countries and USA. www.meditox.eu
SOTIO a.s. SOTIO is a biotechnology company developing a new Active Cellular Immunotherapy (ACI) based on activated dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies. www.sotio.com
AGEL Research a.s. AGEL is the largest private healthcare provider in Central Europe, which has been also operating via its subsidiary, AGEL SK, in Slovakia since 2006. Our company operates hospitals, outpatient clinics, distribution companies, NGOs, and a research entity. With their results, our healthcare facilities rightly belong among the absolute top both within the European Union and worldwide. We offer: research experience, access to a diverse pool of end-users, teams of world class specialists in the field of Oncology, Biochemistry, Cardiology, Paediatrics, Geriatrics, Neurology, Gastroenterology, Internal Medicine, Orthopaedics, Surgery, and an ability to cover projects from the research stage to market implementation. http://www.agelhealth.eu
CzechInvest Business and Investment Development Agency, CzechInvest, is an agency of the Ministry of Industry and Trade. Established in 1992, the agency contributes to attracting foreign investment and developing domestic companies through its services and development programmes. CzechInvest also promotes the Czech Republic abroad and acts as an intermediary between the EU and small and medium-sized enterprises in implementing structural funds in the Czech Republic. www.czechinvest.org/en
The International Clinical Research Center of St. Anne’s University Hospital in Brno The International Clinical Research Centr of St. Anne’s University Hosipital in Brno (FNUSA-ICRC) in Brno, Czech Republic is a new generation science and research centre focusing on finding new methods, technologies, and medicaments for effective prevention, early diagnosics and individualised treatment of cardiovascular and neurological diseases. These are amongst the most widespread diseases in modern society. The center is based onm the hospital’s successful, longtime cooperation with Mayo Clinic (USA) and other partners both in Czech Republic and abroad. www.fnusa-icrc.org
Speaker Profiles Davidson Ateh BioMoti Davidson Ateh is a health entrepreneur. He has an interdisciplinary scientific background in the physical and life sciences having completed a BEng in Biomedical Materials and a PhD in Bioengineering at Queen Mary University of London. He is a past recipient of the prestigious Royal Society of Edinburgh/ BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School (University of Strathclyde). Davidson has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti candidates have the potential to be groundbreaking cancer therapies for patients in need. Through Viafea, he works to promote early stage health innovation in Africa with a focus on entrepreneurial support, network building, access to finance and infrastructure projects.
Tony Jones, Director of Business Development One Nucleus After completing a PhD in Biochemistry (1992) from the University of Southampton UK, Tony undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund (now CRUK). In 1997, he moved into Technology Transfer with the Medical Research Council and later (1998) University College London, at the Wolfson Institute for Biomedical Research. In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and promotion of London’s excellence in healthcare research and delivery. In May 2010 he took London Biotechnology Network into the merger with ERBI, seeing this as the best manner in which to continue assisting member companies develop their businesses. As Director of Business Development his role at One Nucleus encompasses the development of the membership offer to reflect the current external environment and changing needs placed upon members’ businesses. He leads on delivery of the BioWednesday events series and the annual Genesis Conference. As a member of the senior management team of One Nucleus, he remains integral to the content of One Nucleus’ Cambridge-based events and the overall strategy of the company.
Niall McAlister Olswang Niall has over twenty years experience as a corporate lawyer and has a wide experience of mergers and acquisitions, joint ventures and private equity and venture capital transactions. He has acted for a number of clients in the life sciences, advertising, insurance and reinsurance and financial services sectors. He has also led teams on a number of substantial cross-border transactions. He has particular experience representing life sciences clients, having advised both commercial entities and medical research charities on a range of transactions in the sector. He is recognised in directories both for his expertise as a corporate lawyer in the life sciences sector and as a charity lawyer. Niall is recommended for transactions and venture capital investments in the life science sector (Legal 500 UK, 2014). - Advised the owners of Antitope Limited on the sale of the company to PolyTherics Limited - Represented Epidarex Capital on its series A Round investment in Edinburgh Molecular Imaging - Advised Michelson Diagnostics on its Series A2 investment round , led by Octopus Investments - Represented Astellas Venture Managers in relation to its investments in F2G, Bicycle Therapeutics and Crescendo Biologics - Led a cross-border team representing a major international pharmaceutical company on its auction bid for a substantial European pharmaceutical business - Led a Europe-wide team in 16 jurisdictions advising on European aspects of the buy-out of the medical imaging business of Eastman-Kodak (now called Carestream Health) and on the subsequent group restructuring - Advised on a global life sciences client on the disposal of its UK dialysis business - Worked with the Wellcome Trust to structure, finance and complete the spin-out of Kymab Limited from its research campus at Hinxton, Cambridge. This was the first spin-out from a Wellcome Trust research centre - Represented the Wellcome Trust on its joint venture with GlaxoSmithKline to build and operate a bioincubator at Stevenage Bioscience Park. The bioincubator will be the cornerstone facility on the park - Advised on the charitable structure for UKCMRI Limited (now the Francis Crick Institute), a joint venture between MC, UCL, Cancer Research UK and Wellcome Trust, which will create and operate the UK Centre for Medical Research and Innovation at Kings Cross, London, and negotiated the joint venture documentation. He also led negotiations with the Charity Commission on the structure - Led the team that represented the Wellcome Trust on its issue of ÂŁ550mn listed bonds, the first listed bond issuance by a UK chairty, including the creation of a tax efficient limited partnership structure, negotiation with the Charity Commission and extensive legal research - Represented the Wellcome Trust on its accelerated equity offering of a substantial shareholding in GSK - Responsible for drafting and negotiating with the Chairty Commission a new constitution for the Wellcome Trust - Represented a number of biotech companies in fundraising, including Syntaxin, Psynova Neurotech, Navion, Myaction - Advised the Wellcome Trust on a number of investments in European biotech companies
Delegate List First name Davidson Nigel Saadia Jonathan David Simon Thomas Corey Pavel Paul Emma Deborah Julian Paul David Greer Bobby Itziar Harriet Keith
Surname Ateh Banister Basharat Beech Bell Bishop Bjorn Blake Bobek Carnochan Cartwright Cockerill Cooper Cronin Davis Deal Deal Escudero Fear Foster
Viola Paul Joe Tony Pradyp Josef Yvonne Kristin Jirí Patricia Alicja Jan Maria Joao Vojtech Fiona Herve Peter
Galligioni Hopkins Ingram Jones Kanabar Kautzner Kennard Kornerup Krechl Latter Malysiak Marek Martins Melenovský Middleton Mottais Motteram
Petr Chris Roman Tamara Albert
Müller Parsons Pašek Pedgrift Perez-Riba
Company BioMoti Ltd Rare Biotech Ltd Alacrita The Institute of Cancer Research Miramar Executive Search Limited Clinical Network Services (CNS) Pty Ltd Public Health England Paul Hastings (Europe) LLP Embassy of the Czech Republic in London The Institute of Cancer Research Fasken Martineau LLP Sciad Communications Ltd Illingworth Research Limited Clinical Network Services (CNS) Pty Ltd United Airlines Global Regulatory Services Global Regulatory Services Insights in Life Sciences Ltd (ilS) One Nucleus Ipsen Development Ltd The International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC) King's College London Moore Stephens LLP One Nucleus Bio-Analytical Technologies (UK) Limited Institute for Clincal and Experimental Medicine (IKEM) CIMYM BioSciences Ltd Moore Stephens LLP CzechInvest London BioScience Innovation Centre (LBIC) Selvita Ltd. Great Ormond Hospital Life Sciences Sharing Ideas (LSSI) Ltd Institute for Clincal and Experimental Medicine (IKEM) Cancer Research Technology Ltd Moore Stephens LLP P.A.S.M. Limited Regional Centre for Applied Molecular Oncology (RECAMO) UKTI - Trade Services (London) CzechInvest Consultant - Tamara Pedgrift One Nucleus
Jelena Lukas Barbara Dave Clare Nadia Aleksander Richard
Põlajeva Recek Rigby Roberts Sansom Shivji Slemensek Smith
Ondrej David William Natalie Martina Saroj
Sochor Spinner Sprigings Thomas Urbánková Velamakanni
Cathy Martin Justin Adam
Vickers Vodák Wilson Yates
Cancer Research Technology Ltd MediTox Dehns Selcia Limited Dr Clare Sansom (freelance) One Nucleus Advantum Solutions Synexus UK The International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC) Greaves Brewster LLP BioPark Clinical Network Services (CNS) Pty Ltd AGEL Research Fahy Gurteen Laboratories NC3Rs (National Centre for the Replacement, Refinement and Reduction of Animals in Research) SOTIO Withers & Rogers LLP Dehns